ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Gilead invests in cancer immunology-focused Tizona

by Lisa M. Jarvis
July 25, 2020 | APPEARED IN VOLUME 98, ISSUE 29

 

Gilead Sciences is paying $300 million for a 49.9% stake in San Francisco–based Tizona Therapeutics. The centerpiece of the deal is TTX-080, an antibody that targets the immune checkpoint protein HLA-G; it is expected to begin clinical studies in solid cancers this quarter. Gilead can acquire the rest of the firm for up to $1.25 billion after seeing data from Phase Ib studies. The deal does not include TTX-030, an anti-CD39 antibody that Tizona licensed to AbbVie for $105 million last year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment